Clinical Trials for Patients with Dermatomyositis

PROTOCOL GLPG3667-CL-214 A randomized, double-blind, placebo controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis

Clinicatrial.gov Website:

https://www.clinicaltrials.gov/ct2/show/NCT05695950?cond=Dermatomyositis&cntry=
US&state=US%3AMN&draw=2&rank=1

Study website:
https://www.glpg.com/pipeline